490 related articles for article (PubMed ID: 32234682)
21. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
[TBL] [Abstract][Full Text] [Related]
22. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ; Wilson NR; Pemmaraju N
Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm.
Hwang K; Park CJ; Jang S; Chi HS; Huh JR; Lee JH; Suh C; Lee KH
Histopathology; 2013 Apr; 62(5):764-70. PubMed ID: 23470050
[TBL] [Abstract][Full Text] [Related]
24. A systematic literature review of 74 Chinese blastic plasmacytoid dendritic cell neoplasm patients.
Gong C; Liu Y; Zhang M
Ther Adv Hematol; 2024; 15():20406207241251602. PubMed ID: 38832237
[TBL] [Abstract][Full Text] [Related]
25. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
Economides MP; Konopleva M; Pemmaraju N
Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
[TBL] [Abstract][Full Text] [Related]
26. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches.
Pagano L; Valentini CG; Grammatico S; Pulsoni A
Br J Haematol; 2016 Jul; 174(2):188-202. PubMed ID: 27264021
[TBL] [Abstract][Full Text] [Related]
27. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
Pemmaraju N; Kantarjian H
Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496
[TBL] [Abstract][Full Text] [Related]
28. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression.
Tang H; Panse G; Braddock D; Perincheri S; Xu ML; McNiff JM
J Cutan Pathol; 2023 Jul; 50(7):595-600. PubMed ID: 37082914
[TBL] [Abstract][Full Text] [Related]
29. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Luskin MR; Lane AA
Haematologica; 2024 Jan; 109(1):44-52. PubMed ID: 36951152
[TBL] [Abstract][Full Text] [Related]
30. Leukemic manifestation of blastic plasmacytoid dendritic cell neoplasm lacking skin lesion : a borderline case between acute monocytic leukemia.
Takiuchi Y; Maruoka H; Aoki K; Kato A; Ono Y; Nagano S; Arima H; Inoue D; Mori M; Tabata S; Yanagita S; Matsushita A; Nishio M; Imai Y; Imai Y; Ito K; Fujita H; Kadowaki N; Ishikawa T; Takahashi T
J Clin Exp Hematop; 2012; 52(2):107-11. PubMed ID: 23037626
[TBL] [Abstract][Full Text] [Related]
31. [Blastic plasmacytoid dendritic cell neoplasm: A clinico-pathological retrospective analysis of thirteen cases].
Nong L; Wang W; Liang L; Li D; Li X; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):308-314. PubMed ID: 37042142
[TBL] [Abstract][Full Text] [Related]
32. Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights.
Venugopal S; Zhou S; El Jamal SM; Lane AA; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):545-554. PubMed ID: 31281107
[TBL] [Abstract][Full Text] [Related]
33. A CD56- immunoblastoid variant of blastic plasmacytoid dendritic cell neoplasm.
Aran BM; Duran J; Whittemore D; Gru AA
J Cutan Pathol; 2024 Jan; 51(1):40-44. PubMed ID: 37612885
[TBL] [Abstract][Full Text] [Related]
34. Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm.
Sukswai N; Aung PP; Yin CC; Li S; Wang W; Wang SA; Ortega V; Lyapichev K; Nagarajan P; Alfattal R; Angelova E; Tang Z; Loghavi S; Kanagal-Shamanna R; Miranda RN; Pemmaraju N; Bhalla K; Konopleva M; Medeiros LJ; Khoury JD
Am J Surg Pathol; 2019 Oct; 43(10):1429-1437. PubMed ID: 31261288
[TBL] [Abstract][Full Text] [Related]
35. Cytologic features of blastic plasmacytoid dendritic cell neoplasm involving liver: A case report and literature review.
Ding Y; Yang J; Lindsey K
Diagn Cytopathol; 2021 Feb; 49(2):E80-E83. PubMed ID: 32852895
[TBL] [Abstract][Full Text] [Related]
36. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wilson NR; Pemmaraju N
Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
[TBL] [Abstract][Full Text] [Related]
37. An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality.
Sumarriva Lezama L; Chisholm KM; Carneal E; Nagy A; Cascio MJ; Yan J; Chang CC; Cherry A; George TI; Ohgami RS
Histopathology; 2018 Nov; 73(5):767-776. PubMed ID: 29884995
[TBL] [Abstract][Full Text] [Related]
38. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
39. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents.
Wang S; Wang X; Liu M; Bai O
Ann Hematol; 2018 Apr; 97(4):563-572. PubMed ID: 29455234
[TBL] [Abstract][Full Text] [Related]
40. An unusual case of cutaneous blastic plasmacytoid dendritic cell neoplasm with concomitant B-cell lymphoproliferative disorder.
Patel JL; Shetty S; Salama ME
Am J Dermatopathol; 2011 May; 33(3):e31-6. PubMed ID: 20861710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
